DEF 14A: Denali Capital Acquisition Corp. Seeks Shareholder Approval for Extension Amid Merger Termination

Denali Capital Acquisition Corp. is seeking shareholder approval to extend the deadline for completing a business combination to April 11, 2025, after terminating its merger agreement with Longevity Biomedical, Inc.

Summary

• Denali Capital Acquisition Corp. is holding an extraordinary general meeting on July 10, 2024, to vote on a proposal to extend the date by which it must complete an initial business combination from July 11, 2024, to April 11, 2025.
• The company's initial merger agreement with Longevity Biomedical, Inc. was terminated on June 26, 2024.
• The extension requires an amendment to the company's amended and restated memorandum and articles of association.
• If approved, the Sponsor will deposit into the trust account the lesser of $20,000 or $0.02 per public share for each one-month extension, up to nine months, in exchange for a non-interest bearing promissory note.
• Shareholders can redeem their Class A ordinary shares for approximately $11.43 per share, based on the amount in the trust account as of the record date.
• If the extension is not approved, the company will liquidate and dissolve, with no distribution for warrants.
• The Sponsor and certain directors and officers, who own approximately 23.8% of the company's shares, are expected to vote in favor of the extension.
• The company is also seeking approval for an adjournment proposal to allow for further solicitation of proxies if needed.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. The termination of the merger agreement is a setback, but the company is actively seeking an extension and alternative business combinations. The potential for shareholder redemptions and liquidation adds uncertainty.

Positives

• The extension provides additional time to find and complete a business combination, potentially benefiting shareholders.
• The Sponsor is willing to invest additional funds (up to $180,000) to facilitate the extension.
• Shareholders retain the right to redeem their shares if they do not approve of the extension or any future business combination.

Negatives

• The termination of the merger agreement with Longevity Biomedical, Inc. is a setback.
• If the extension is not approved, the company will liquidate, and warrants will expire worthless.
• Redemption of shares will reduce the net asset value and the amount held in the trust account.
• There is no guarantee that a suitable business combination can be found even with the extension.

Risks

• There is no assurance that the extension will enable the company to complete an initial business combination.
• Redemptions could leave the company with insufficient cash to consummate a business combination.
• The company could be deemed an investment company, requiring liquidation.
• The Sponsor and directors may have conflicts of interest.
• A 1% U.S. federal excise tax may decrease the value of the securities following an initial business combination.
• The company may not be able to complete an initial business combination with a U.S. target company if such initial business combination would be subject to U.S. foreign investment regulations and review by a U.S. government entity such as the Committee on Foreign Investment in the United States (CFIUS), or is ultimately prohibited.

Future Outlook

The company intends to seek alternative ways to consummate an initial business combination and will continue to attempt to do so until the Extended Date if the extension is approved.

Management Comments

• The Board believes that it is in the best interests of the Company to continue our existence until the Extended Date, if necessary, in order to allow us more time to complete an initial business combination.
• The Board believes that there will not be sufficient time before the Termination Date to complete an initial business combination.
• The Board believes that in order to be able to consummate an initial business combination, we will need to obtain the extension.

Industry Context

This announcement is typical for SPACs approaching their termination date without a completed business combination. Many SPACs seek extensions to continue searching for suitable targets, often requiring additional investment from the sponsor and potentially leading to shareholder redemptions.

Comparison to Industry Standards

• Seeking extensions is a common practice among SPACs facing their initial deadlines.
• The amount of the sponsor contribution for the extension ($20,000 or $0.02 per share per month) is within the typical range seen in similar situations.
• The redemption price of approximately $11.43 is comparable to the initial IPO price plus accrued interest in the trust account, which is standard for SPAC redemptions.
• Comparable companies that have sought extensions include Fortune Rise Acquisition Corporation (Nasdaq: FRLA) and Feutune Light Acquisition Corporation (Nasdaq: FLFV).

Related Party Transactions

• The Sponsor paid $25,000 for Class B Ordinary Shares.
• The company completed the sale to the Sponsor of an aggregate of 510,000 Private Placement Units for a purchase price of $10.00 per whole warrant for an aggregate of $5,100,000.
• The company entered into the Sponsor Letter Agreement with the Sponsor.
• The company issued a convertible promissory note in the total principal amount of up to $1,200,000 to the Sponsor.

Stakeholder Impact

• Shareholders have the option to redeem their shares, potentially reducing the company's cash reserves.
• If the company liquidates, warrant holders will receive no distribution.
• The Sponsor and management team face the risk of losing their investment if a business combination is not completed.

Next Steps

• Shareholders will vote on the extension amendment proposal and the adjournment proposal on July 10, 2024.
• If the extension is approved, the company will continue to seek an initial business combination until April 11, 2025.
• The company intends to withdraw its registration statement on Form S-4.

Key Dates

Keywords

business combination, extension, redemption, SPAC, liquidation, sponsor, merger, proxy statement, shareholders, Denali Capital